Page last updated: 2024-11-11

ceftiofur

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ceftiofur: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6328657
CHEMBL ID222913
SCHEMBL ID332041
MeSH IDM0151563
PubMed CID16212182
SCHEMBL ID16072838
MeSH IDM0151563

Synonyms (53)

Synonym
ceftiofur (inn)
D07657
CHEMBL222913
ceftiofur crystalline free acid
A839898
(6r,7r)-7-[[(2z)-2-(2-azanyl-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-3-(furan-2-ylcarbonylsulfanylmethyl)-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[[(2z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-[[[2-furanyl(oxo)methyl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
tox21_112540
cas-80370-57-6
dtxcid5026702
dtxsid7046702 ,
AKOS015998831
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo-, (6r,7r)-
unii-83jl932i1c
hsdb 7445
ceftiofur [usan:inn:ban]
ceftiofurum [latin]
(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(mercaptomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-(o-methyloxime), 2-furoate (ester)
83jl932i1c ,
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo-, (6r-(6alpha,7beta(z)))-
ceftiofur [mi]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo-, (6r-(6.alpha.,7.beta.(z)))-
ceftiofur [hsdb]
ceftiofur [mart.]
ceftiofur crystalline free acid [green book]
ceftiofur [inn]
ceftiofur [ema epar veterinary]
ceftiofur [who-dd]
S5356
SCHEMBL332041
(6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(((furan-2-carbonyl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(furan-2-carbonylsulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
bdbm50103524
HY-N7102
DB11485
BRD-K82960980-003-02-7
CCG-269876
CS-0081818
ceftiofur 100 mug/ml in acetonitrile/water
ceftiofur (ema epar veterinary)
ceftiofur free acid
excedesterile
(6r,7r)-7-
ceftiofurum (latin)
naxcel (veterinary)
excede for swinesterile
ceftiofur (mart.)
80370-57-6
ceftiofur
(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SCHEMBL16072838
ceftiofur, vetranal(tm), analytical standard
(7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Research Excerpts

Toxicity

Ceftiofur sodium, a broad-spectrum cephalosporin antibiotic, was evaluated for safe use in horses.

ExcerptReferenceRelevance
"Ceftiofur sodium, a broad-spectrum cephalosporin antibiotic, was evaluated for safe use in horses."( Safety of ceftiofur sodium administered intramuscularly in horses.
Mahrt, CR, 1992
)
0.28
"OBJECTIVE To determine the pharmacokinetics and adverse effects following SC administration of ceftiofur crystalline free acid (CCFA) in New Zealand White rabbits."( Pharmacokinetics and safety of ceftiofur crystalline free acid in New Zealand White rabbits (Oryctolagus cuniculus).
Byrne, BA; Cox, S; Drazenovich, TL; Gardhouse, S; Guzman, DS; Hawkins, MG; Kass, PH, 2017
)
0.46
" The aim of this report is to describe the clinical presentation of an adverse drug reaction after the intramuscular administration of ceftiofur hydrochloride."( Ceftiofur Side Effect in a Mare-Case Report.
da Silva Azevedo, M; Duarte, CA; Góss, GC; Pradella, GD; Taschetto, PM, 2020
)
0.56

Pharmacokinetics

The pharmacokinetic profile of ceftiofur is altered in PRRSV-infected pigs. CCFA is an economical, injectable antibiotic that could be of value for use in research dogs. The objective of this study was to determine the pharmacokinetics of CCFA in apparently healthy dogs.

ExcerptReferenceRelevance
" Therefore this study evaluated potential pharmacokinetic interactions between ceftiofur sodium and aspirin."( The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid.
Freeman, DA; Hanlon, D; Parton, K; Whittem, T, 1995
)
0.29
" Cmax values were similar in all calves, and were no higher in younger calves than in older calves."( Effects of age on the pharmacokinetics of single dose ceftiofur sodium administered intramuscularly or intravenously to cattle.
Brown, SA; Chester, ST; Robb, EJ, 1996
)
0.29
" administration, whereas a Cmax of 13."( Comparison of plasma pharmacokinetics and bioequivalence of ceftiofur sodium in cattle after a single intramuscular or subcutaneous injection.
Brown, SA; Callahan, JK; Chester, ST; Hamlow, PJ; Hibbard, B; Hubbard, VL; Robb, EJ; Speedy, AK, 2000
)
0.31
" Often treatment regimens are established with no pharmacokinetic data on the agents being used for treatment in these species."( Pharmacokinetics and i.m. bioavailability of ceftiofur in Asian elephants (Elephas maximus).
Dumonceaux, G; Hunter, RP; Isaza, R; Koch, DE, 2005
)
0.33
"To compare the pharmacokinetic profile of ceftiofur hydrochloride (ceftiofur) administered intramuscularly at 3 mg/kg body weight (BW) in pigs infected with porcine reproductive and respiratory syndrome virus (PRRSV) versus clinically healthy pigs."( Pharmacokinetics of ceftiofur hydrochloride in pigs infected with porcine reproductive and respiratory syndrome virus.
Nilubol, D; Tantituvanont, A; Werawatganone, P; Yimprasert, W, 2009
)
0.35
" Pharmacokinetic parameters of ceftiofur were calculated based on non-compartmental analysis."( Pharmacokinetics of ceftiofur hydrochloride in pigs infected with porcine reproductive and respiratory syndrome virus.
Nilubol, D; Tantituvanont, A; Werawatganone, P; Yimprasert, W, 2009
)
0.35
"The pharmacokinetic profile of ceftiofur is altered in PRRSV-infected pigs due to the decreased plasma ceftiofur concentration compared with clinically healthy pigs."( Pharmacokinetics of ceftiofur hydrochloride in pigs infected with porcine reproductive and respiratory syndrome virus.
Nilubol, D; Tantituvanont, A; Werawatganone, P; Yimprasert, W, 2009
)
0.35
"The main pharmacokinetic parameters for the control group were C(max) = 21."( [Effect of ceftiofur hydrochloride on pharmacokinetics of matrine in rats].
He, X; Li, Z; Liao, D; Zhao, C; Zuo, H, 2010
)
0.36
" This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5 mg/kg body weight; n = 6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6."( Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals.
Fowler, LW; Hall, TL; McCormick, JD; Pusterla, N; Tell, LA; Wetzlich, SE, 2011
)
0.37
" Mean (±SD) pharmacokinetic parameters were as follows for the nonlactating goats: area under the concentration time curve(0-∞) (159 h·μg/mL ± 19), maximum observed serum concentration (2."( Pharmacokinetics of ceftiofur crystalline free acid after single subcutaneous administration in lactating and nonlactating domestic goats (Capra aegagrus hircus).
Angelos, JA; Carlson, JL; Doré, E; Kieu, HT; Rowe, JD; Tell, LA; Wetzlich, SE, 2011
)
0.37
" The harmonic mean ± pseudo-SD terminal half-life of ceftiofur was 29."( Pharmacokinetics of long-acting ceftiofur crystalline-free acid in helmeted guineafowl (Numida meleagris) after a single intramuscular injection.
Adkesson, MJ; Cox, SK; Gamble, KC; Langan, JN; Wojick, KB, 2011
)
0.37
" Pharmacokinetic disposition of CCFA was analyzed by a noncompartmental approach."( Pharmacokinetics of ceftiofur crystalline free acid after single and multiple subcutaneous administrations in healthy alpacas (Vicugna pacos).
Byrne, BA; Dechant, JE; Kieu, HT; Rowe, JD; Tell, LA; Wetzlich, SE, 2013
)
0.39
"To determine the pharmacokinetic properties of 1 IM injection of ceftiofur crystalline-free acid (CCFA) in American black ducks (Anas rubripes)."( Pharmacokinetics of a single intramuscular injection of ceftiofur crystalline-free acid in American black ducks (Anas rubripes).
Boedeker, NC; Byrne, BA; Hope, KL; Lynch, W; Murray, S; Padilla, LR; Tell, LA; Ware, LH; Wetzlich, SE, 2012
)
0.38
"1 μg/mL, time to maximum plasma concentration observed was 24 hours, terminal phase half-life was 32."( Pharmacokinetics of a single intramuscular injection of ceftiofur crystalline-free acid in American black ducks (Anas rubripes).
Boedeker, NC; Byrne, BA; Hope, KL; Lynch, W; Murray, S; Padilla, LR; Tell, LA; Ware, LH; Wetzlich, SE, 2012
)
0.38
" A noncompartmental pharmacokinetic analysis was applied to the data."( Pharmacokinetics of a long-acting ceftiofur formulation (ceftiofur crystalline free acid) in the ball python (Python regius).
Adkesson, MJ; Cox, S; Fernandez-Varon, E; Martín-Jiménez, T, 2011
)
0.37
" The terminal elimination half-life associated with the slope of the terminal phase had a harmonic mean ± pseudo-SD of 83."( Pharmacokinetics of a long-acting ceftiofur crystalline-free acid formulation in Asian elephants (Elephas maximus).
Adkesson, MJ; Allender, MC; Junge, RE; Martín-Jiménez, T, 2012
)
0.38
" Pharmacokinetic parameters were determined by compartmental and noncompartmental methods."( Pharmacokinetics of ceftiofur crystalline-free acid following subcutaneous administration of a single dose to sheep.
Angelos, JA; Byrne, BA; Rivera-Garcia, S; Rowe, JD; Tell, LA; Van Liew, DB; Wetzlich, SE, 2014
)
0.4
"In a preliminary experiment, doses of 15 and 30 mg/kg, SC, were compared in 2 animals, and 30 mg/kg resulted in a more desirable pharmacokinetic profile."( Pharmacokinetics of subcutaneous versus intramuscular administration of ceftiofur crystalline-free acid to bearded dragons (Pogona vitticeps).
Churgin, SM; Cox, SK; Musgrave, KE; Sladky, KK, 2014
)
0.4
"Administration of ceftiofur sodium via nebulisation has been recommended for the treatment of bronchopneumonia in horses, despite the lack of pharmacokinetic and safety data."( Pulmonary pharmacokinetics of desfuroylceftiofur acetamide after nebulisation or intramuscular administration of ceftiofur sodium to weanling foals.
Berghaus, LJ; Fultz, L; Giguère, S; Grover, GS; Merritt, DA, 2015
)
0.42
"This study determined the impact of porcine reproductive and respiratory syndrome virus (PRRSV) and Streptococcus suis coinfection on the pharmacokinetic (PK) profile of ceftiofur hydrochloride in pigs after intramuscular (i."( Impact of an experimental PRRSV and Streptococcus suis coinfection on the pharmacokinetics of ceftiofur hydrochloride after intramuscular injection in pigs.
Coetzee, JF; Day, DN; Ellingson, J; Gehring, R; Karriker, LA; Kinyon, JM; Sparks, JW; Stalder, KJ; Stock, ML; Wang, C; Wulf, LW; Zhang, J, 2015
)
0.42
" We describe the pharmacokinetic profile of CCFA in healthy, adult male rhesus macaques ( n = 6) in this 2-period, 2-treatment crossover study of 5 and 20 mg/kg SC administered once."( Pharmacokinetics of Ceftiofur Crystalline Free Acid in Male Rhesus Macaques (Macaca mulatta) after Subcutaneous Administration.
Christe, KL; Hill, AE; Kelly, KR; Knych, HK; Salyards, GW, 2015
)
0.42
"The objective of this study was to compare the plasma pharmacokinetic profile of ceftiofur crystalline-free acid (CCFA) and ceftiofur sodium in neonatal calves between 4 and 6 days of age."( Comparative plasma pharmacokinetics of ceftiofur sodium and ceftiofur crystalline-free acid in neonatal calves.
Caldwell, M; Cox, S; Credille, BC; Hines, M; Woodrow, JS, 2016
)
0.43
" Compared with control cows, the disease group had an initially higher peak concentration and a higher volume of distribution and drug clearance rates."( Altered plasma pharmacokinetics of ceftiofur hydrochloride in cows affected with severe clinical mastitis.
Coetzee, JF; Gorden, PJ; Kleinhenz, MD; KuKanich, B; Lee, CJ; Wang, C; Wulf, LW, 2016
)
0.43
" Pharmacokinetic data were calculated."( Pharmacokinetics of a single intramuscular injection of ceftiofur crystalline-free acid in red-tailed hawks (Buteo jamaicensis).
Byrne, BA; Cartoceti, AN; Drazenovich, TL; Hawkins, MG; Keel, K; Sadar, MJ; Tell, LA, 2015
)
0.42
" Because CCFA is an economical, injectable antibiotic that could be of value for use in research dogs, the objective of this study was to determine the pharmacokinetic properties of CCFA in apparently healthy dogs and to determine the minimal inhibitory concentrations of ceftiofur for veterinary pathogens cultured during 2011 through 2014 from the respiratory system, integumentary system, and urinary system of dogs."( Pharmacokinetics of Ceftiofur Crystalline-Free Acid in Clinically Healthy Dogs (Canis lupus familiaris).
Davis, JL; Dixon, LW; Fales, WH; Giguère, S; Hooper, SE; Korte, SW, 2016
)
0.43
" Concentrations of ceftiofur in plasma were determined by use of high-performance liquid chromatography, and pharmacokinetic parameters were calculated on the basis of noncompartmental methods."( Comparative pharmacokinetics of ceftiofur hydrochloride and ceftiofur sodium after administration to water buffalo (Bubalus bubalis).
Feng, X; He, J; Liang, L; Lu, C; Nie, H; Peng, J; Tang, S; Tiwari, RV, 2016
)
0.43
" Terminal half-life was significantly (p = ."( Pharmacokinetics of ceftiofur sodium in equine pregnancy.
Benson, SA; Giguère, S; Hatzel, JN; Kelleman, AA; Larson, J; LeBlanc, MM; Macpherson, ML; Pozor, MA; Runcan, E; Sanchez, LC; Troedsson, MHT; Vanden Berg, E; Vickroy, TW, 2017
)
0.46
" Plasma concentrations of CS and all desfuroylceftiofur-related metabolites were determined using HPLC, and its pharmacokinetic properties were determined based on a two-compartment model."( Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy.
Altan, F; Cetin, G; Dik, B; Elmas, M; Er, A; Uney, K; Yazar, E, 2017
)
0.46
" Pharmacokinetic parameters were calculated."( Pharmacokinetics and safety of ceftiofur crystalline free acid in New Zealand White rabbits (Oryctolagus cuniculus).
Byrne, BA; Cox, S; Drazenovich, TL; Gardhouse, S; Guzman, DS; Hawkins, MG; Kass, PH, 2017
)
0.46
"We determined the pharmacokinetic properties of ceftiofur crystalline-free acid (CCFA), a long-acting antibiotic, after a single intramuscular injection in cattle egrets ( Bubulcus ibis)."( Pharmacokinetics of a Single Intramuscular Injection of Long-Acting Ceftiofur Crystalline-Free Acid in Cattle Egrets ( Bubulcus ibis).
Armstrong, DL; Cox, SK; Waldoch, JA, 2017
)
0.46
"007), terminal half-life was significantly longer (p = 0."( Comparative plasma and interstitial fluid pharmacokinetics and tissue residues of ceftiofur crystalline-free acid in cattle with induced coliform mastitis.
Brick, TA; Coetzee, JF; Gorden, PJ; Griffith, RW; Kleinhenz, MD; Mochel, JP; Rajewski, SM; Sidhu, PK; Smith, JS; Wulf, LW; Ydstie, JA; Zhang, M, 2018
)
0.48

Compound-Compound Interactions

The purpose of this study was to determine the activities of two antibacterial agents used in the treatment of bovine respiratory infections-tulathromycin, a macrolide, and ceftiofur, a third-generation cephalosporin-alone. In time-kill analyses, at concentrations above the MICs, ceftIOfur in combination with α-spinasterol exhibited time- dependency and concentration-dependency comparing to time dependency with ceft iofur alone.

ExcerptReferenceRelevance
"The purpose of the present clinical studies was to determine the clinical efficacy of a combined parenteral and oral treatment with Bisolvon in combination with antibiotics in bovines suffering from acute respiratory disease."( [Treatment of acute respiratory tract diseases in cattle with Bisolvon in combination with either enrofloxacin, cefquinome, ceftiofur or florfenicol].
Hamel, U; Philipp, H; Quirke, JF; Schmidt, H, 1998
)
0.3
"The purpose of this study was to determine the activities of two antibacterial agents used in the treatment of bovine respiratory infections-tulathromycin, a macrolide, and ceftiofur, a third-generation cephalosporin-alone, in combination with each other, and in combination with each of seven additional antibiotics (tilmicosin, florfenicol, enrofloxacin, danofloxacin, ampicillin, tetracycline, and penicillin G) against bovine Pasteurella multocida (n = 60) and Mannheimia haemolytica (n = 10) isolates for determination of synergy, antagonism, or indifference."( In vitro activities of tulathromycin and ceftiofur combined with other antimicrobial agents using bovine Pasteurella multocida and Mannheimia haemolytica isolates.
Brumbaugh, GW; Sweeney, MT; Watts, JL, 2008
)
0.35
") administration of ceftiofur was used for five days in combination with flunixin for three days."( Treatment of dairy cows with PGF2α or NSAID, in combination with antibiotics, in cases of postpartum uterine inflammation.
Jeremejeva, J; Kask, K; Orro, T; Waldmann, A, 2012
)
0.38
" In time-kill analyses, at concentrations above the MICs, ceftiofur in combination with α-spinasterol exhibited time-dependency and concentration-dependency comparing to time dependency with ceftiofur alone."( A novel method for synthesis of α-spinasterol and its antibacterial activities in combination with ceftiofur.
Cai, Y; Chen, H; Dong, Q; Li, Y; Rong, Q; Shi, F; Tang, H; Wang, T; Xu, M; Yang, X; Ye, G; Zhao, L; Zhou, J; Zhou, X, 2017
)
0.46

Bioavailability

Ceftiofur sodium was well absorbed following SC and SC-LA administration, with absolute bioavailabilities (F) of 85. The area under the curve from time 0 to the limit of quantitation (AUC0 LOQ) was dose-proportional from 1.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Two studies were designed to compare the intramuscular bioavailability of the current sodium salt and the new hydrochloride salt in pigs at doses of either 3 mg or 5 mg ceftiofur equivalents (CE)/kg body weight."( Comparison of plasma pharmacokinetics and bioavailability of ceftiofur sodium and ceftiofur hydrochloride in pigs after a single intramuscular injection.
Brown, SA; Callahan, JK; Hamlow, PJ; Hanson, BJ; Hubbard, VL; Kausche, FM; Mignot, A; Millérioux, L, 1999
)
0.3
" bioavailability was 19%."( Pharmacokinetics and i.m. bioavailability of ceftiofur in Asian elephants (Elephas maximus).
Dumonceaux, G; Hunter, RP; Isaza, R; Koch, DE, 2005
)
0.33
"The plasma concentration of matrine and bioavailability in combination group were significantly lower than those of the control group."( [Effect of ceftiofur hydrochloride on pharmacokinetics of matrine in rats].
He, X; Li, Z; Liao, D; Zhao, C; Zuo, H, 2010
)
0.36
"Absolute bioavailability and dose proportionality studies were performed with ceftiofur in horses."( Pharmacokinetics of ceftiofur crystalline-free acid sterile suspension in the equine.
Boucher, JF; Brown, SA; Collard, WT; Cox, SR; Grover, GS; Hallberg, JW; Lesman, SP; Robinson, JA, 2011
)
0.37
"OBJECTIVE To evaluate pharmacokinetics and bioavailability after administration of ceftiofur hydrochloride and ceftiofur sodium to water buffalo (Bubalus bubalis)."( Comparative pharmacokinetics of ceftiofur hydrochloride and ceftiofur sodium after administration to water buffalo (Bubalus bubalis).
Feng, X; He, J; Liang, L; Lu, C; Nie, H; Peng, J; Tang, S; Tiwari, RV, 2016
)
0.43
" injection of ceftiofur, plasma concentrations were best described by a 1-compartment open model with a first order absorption; bioavailability was quite high (96."( Ceftiofur pharmacokinetics in Nile tilapia Oreochromis niloticus after intracardiac and intramuscular administrations.
Abdou, RH; Khalil, WF; Shaheen, HM, 2016
)
0.43
" Ceftiofur was well absorbed following SC and SC-LA administration, with absolute bioavailabilities (F) of 85."( Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats.
Cárceles-García, C; Cárceles-Rodríguez, CM; Fernández-Varón, E; Serrano-Rodríguez, JM, 2016
)
0.43
" The objectives of this study were (a) to determine the absolute bioavailability of CEF crystalline-free acid (CFA) in healthy versus diseased cows; (b) to compare the plasma and interstitial fluid pharmacokinetics and plasma protein binding of CEF between healthy dairy cows and those with disease; and (c) to determine the CEF residue profile in tissues of diseased cows."( Comparative plasma and interstitial fluid pharmacokinetics and tissue residues of ceftiofur crystalline-free acid in cattle with induced coliform mastitis.
Brick, TA; Coetzee, JF; Gorden, PJ; Griffith, RW; Kleinhenz, MD; Mochel, JP; Rajewski, SM; Sidhu, PK; Smith, JS; Wulf, LW; Ydstie, JA; Zhang, M, 2018
)
0.48

Dosage Studied

Six adult male alpacas received one subcutaneous administration of ceftiofur crystalline free acid (CCFA) to combat Haemophilus parasuis. Three female Holstein dairy calves were treated by intramuscular injection with EXCENEL RTU at a therapeutic dosage of 2.

ExcerptRelevanceReference
" These dosages are expressed in terms of the ceftiofur free acid, and represent 1 to 5 times the proposed therapeutic dosage (2."( Safety of ceftiofur sodium administered intramuscularly in horses.
Mahrt, CR, 1992
)
0.28
"4 mg/kg of body weight, with 4 wk intervals between dosing regimens."( Pharmacokinetic evaluation of ceftiofur in serum, tissue chamber fluid and bronchial secretions from healthy beef-bred calves.
Baker, JC; Halstead, SL; Hauptman, JG; Holland, RE; Stein, GE; Walker, RD, 1992
)
0.28
" In conclusion, with the exception of the staphylococci, both XNL and DXNL were highly active against the organisms tested, with MICs for both compounds several fold lower than plasma levels achieved during dosing of XNL."( In vitro activity of ceftiofur and its primary metabolite, desfuroylceftiofur, against organisms of veterinary importance.
Salmon, SA; Watts, JL; Yancey, RJ, 1996
)
0.29
" bolus dosing were determined by reverse phase HPLC."( The disposition of five therapeutically important antimicrobial agents in llamas.
Christensen, JM; Hollingshead, N; Murdane, SB; Smith, BB, 1996
)
0.29
" Group 1 calves were dosed at 7 days of age and at 1 and 3 months of age; group 2 calves were dosed at 6 and 9 months of age."( Effects of age on the pharmacokinetics of single dose ceftiofur sodium administered intramuscularly or intravenously to cattle.
Brown, SA; Chester, ST; Robb, EJ, 1996
)
0.29
" The analysis indicated that bovine milk collected 32 h after dosing with ceftiofur was above the FDA tolerance of 50 ppb, while milk collected 48 h after dosing was found to contain 24-31 ppb of ceftiofur."( Quantitative determination of ceftiofur in milk by liquid chromatography-electrospray mass spectrometry.
Keever, J; Tyczkowska, KL; Voyksner, RD, 1998
)
0.3
") dosing (cockatiels and Amazon parrots)."( Pharmacokinetics of ceftiofur sodium in exotic and domestic avian species.
Caputo, J; Craigmill, A; Harrenstien, L; Hoffman, G; Nappier, J; Needham, M; Tell, L; Wetzlich, S, 1998
)
0.3
"The use of Sodium-Ceftiofur (Excenel) with a dosage regimen of 1 mg/kg body mass intramuscularly was evaluated in the therapy of complicated claw diseases, like septic arthritis of the distal interphalangeal joint, septic tenosynovitis of the digital flexor tendon sheath or complicated interdigital necrosis."( [Use of sodium ceftiofur in the combined therapy of complicated septic diseases in cattle].
Kofler, J; Stanek, C, 1998
)
0.3
" In the 3 mg/kg dosage study, average maximum plasma concentration (C(max)) after administration of ceftiofur sodium was 15."( Comparison of plasma pharmacokinetics and bioavailability of ceftiofur sodium and ceftiofur hydrochloride in pigs after a single intramuscular injection.
Brown, SA; Callahan, JK; Hamlow, PJ; Hanson, BJ; Hubbard, VL; Kausche, FM; Mignot, A; Millérioux, L, 1999
)
0.3
"Three studies were conducted to determine and confirm the effective dosage rate of ceftiofur crystalline-free acid sterile suspension (CCFA-SS, 200 mg ceftiofur equivalents [CE]/ml), a long-acting ceftiofur formulation, for control and treatment of bovine respiratory disease (BRD)."( Dose determination and confirmation for ceftiofur crystalline-free acid administered in the posterior aspect of the ear for control and treatment of bovine respiratory disease.
Bryson, WL; Chester, ST; Dame, KJ; Hibbard, B; Moseley, WW; Robb, EJ, 2002
)
0.31
" Two preliminary dosage titration studies using a challenge model compared the efficacy of ceftiofur (1."( A comprehensive review of ceftiofur sodium and hydrochloride formulations for treatment of acute bovine foot rot.
Kausche, FM; Robb, EJ, 2003
)
0.32
"A suggested dosing schedule for ceftiofur sodium in green iguanas for microbes susceptible at > 2 microg/mL would be 5 mg/kg, IM or SC, every 24 hours."( Pharmacokinetics of ceftiofur sodium after intramuscular or subcutaneous administration in green iguanas (Iguana iguana).
Benson, KG; Craigmill, AL; Tell, LA; Wetzlich, S; Young, LA, 2003
)
0.32
" dosing and following ballistic implant were quite different."( Pharmacokinetics of ceftiofur in red deer (Cervus elaphus).
Craigmill, AL; Drew, ML; Kreeger, T; Mackintosh, C; Waldrup, K; Wetzlich, SE, 2004
)
0.32
"9% NaCl) solution administered at a dosage of 2 mL/45."( Efficacy of ceftiofur hydrochloride sterile suspension administered parenterally for the treatment of acute postpartum metritis in dairy cows.
Chenault, JR; Chester, ST; Dame, KJ; Kausche, FM; McAllister, JF; Robb, EJ, 2004
)
0.32
"3% of serovar Newport strains isolated from the turkey poult intestinal tract after the animals were dosed with Escherichia coli harboring a large conjugative plasmid encoding the CMY-2 beta-lactamase and other drug resistance determinants acquired the plasmid and its associated drug resistance genes."( Acquisition of resistance to extended-spectrum cephalosporins by Salmonella enterica subsp. enterica serovar Newport and Escherichia coli in the turkey poult intestinal tract.
Boerlin, P; Forward, KR; Gyles, CL; Martin, LC; McEwen, SA; Poppe, C; Prescott, JF; Reid-Smith, R, 2005
)
0.33
" Chamber fluid and blood samples were collected at predetermined times for 10 days following dosing and analyzed for ceftiofur and desfuroylceftiofur metabolites by high-performance liquid chromatography."( Penetration of ceftiofur into sterile vs. Mannheimia haemolytica-infected tissue chambers in beef calves after subcutaneous administration of ceftiofur crystalline free acid sterile suspension in the ear pinna.
Anderson, K; Bryson, W; Callahan, K; Clarke, CR; Dame, K; Hubbard, V; Johnson, R; Lucas, M; Robb, E; Robinson, J; Washburn, K, 2005
)
0.33
" All calves were dosed with ceftiofur crystalline free acid sterile suspension (CCFA-SS) subcutaneously in the ear pinna."( Distribution of ceftiofur into Mannheimia haemolytica-infected tissue chambers and lung after subcutaneous administration of ceftiofur crystalline free acid sterile suspension.
Anderson, K; Clarke, C; Johnson, R; Washburn, K, 2010
)
0.36
" Six healthy, adult cows in two treatment groups were dosed intravenously with ceftiofur sodium liposomes and ceftiofur sodium, serial blood samples collected, and plasma concentrations determined by high performance liquid chromatography."( Preparation and pharmacokinetics of ceftiofur sodium liposomes in cows.
Guo, D; Guo, Y; Liu, S; Zhou, W, 2011
)
0.37
"On the basis of the time that CFAE concentrations were higher than the target plasma concentration, a dosing interval of 3 days can be recommended for future multidose CCFA studies."( Pharmacokinetics of a single intramuscular injection of ceftiofur crystalline-free acid in American black ducks (Anas rubripes).
Boedeker, NC; Byrne, BA; Hope, KL; Lynch, W; Murray, S; Padilla, LR; Tell, LA; Ware, LH; Wetzlich, SE, 2012
)
0.38
" Dosing to achieve MPC concentrations (where possible) may serve to reduce the selection of bacterial subpopulations with reduced antimicrobial susceptibility."( Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica.
Blondeau, BJ; Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, CE, 2012
)
0.38
"5 microg/ml, more frequent dosing or a higher dosage may be required."( Pharmacokinetics of a long-acting ceftiofur formulation (ceftiofur crystalline free acid) in the ball python (Python regius).
Adkesson, MJ; Cox, S; Fernandez-Varon, E; Martín-Jiménez, T, 2011
)
0.37
" Results of the part I (internal) and part II (independent laboratory) dose-response studies employing spiked samples were in close agreement."( Validation study of the BetaStar plus lateral flow assay for detection of beta-lactam antibiotics in milk.
Abouzied, M; Ankrapp, D; Driksna, D; Klein, F; Mozola, M; Rice, J; Sarzynski, M; Walsh, A; Walsh, C,
)
0.13
" Dosing recommendations will depend on the mean inhibitory concentration of ceftiofur for each bacterial pathogen."( Pharmacokinetics of a long-acting ceftiofur crystalline-free acid formulation in Asian elephants (Elephas maximus).
Adkesson, MJ; Allender, MC; Junge, RE; Martín-Jiménez, T, 2012
)
0.38
" There are currently no data to guide an appropriate dosing interval when a longer treatment regimen is warranted."( Plasma and pulmonary pharmacokinetics of desfuroylceftiofur acetamide after weekly administration of ceftiofur crystalline free acid to adult horses.
Berghaus, LJ; Davis, JL; Fultz, L; Giguère, S, 2014
)
0.4
" Concentrations of DCA in plasma and PELF remained in the therapeutic range for the entire dosing interval."( Plasma and pulmonary pharmacokinetics of desfuroylceftiofur acetamide after weekly administration of ceftiofur crystalline free acid to adult horses.
Berghaus, LJ; Davis, JL; Fultz, L; Giguère, S, 2014
)
0.4
" One-day-old chicks were each dosed subcutaneously with ceftiofur and samples taken from day 1 to day 44 post-dosing."( Can the unauthorised use of ceftiofur be detected in poultry?
Chan, D; Fussell, RJ; Heinrich, K; Kay, JF; Sharman, M, 2013
)
0.39
" Incurred tissue samples were obtained from dosed animals and analyzed to evaluate the utility of the method."( Determination of ceftiofur metabolite desfuroylceftiofur cysteine disulfide in bovine tissues using liquid chromatography-tandem mass spectrometry as a surrogate marker residue for ceftiofur.
Chattopadhaya, C; Chiesa, OA; Feng, S; Girard, L; Kijak, P; Lancaster, V; Li, H; Sklenka, S; Smith, EA, 2014
)
0.4
" The method was fully validated over a dosing range between 100 and 2000 μg kg(-1) (or μg L(-1)) using the total error approach."( Validation of a liquid chromatography-high-resolution mass spectrometry method for the analysis of ceftiofur in poultry muscle, kidneys and plasma: A unique accuracy profile for each and every matrix.
Abjean, JP; Fourmond, MP; Hurtaud-Pessel, D; Laurentie, M; Mompelat, S; Verdon, E, 2015
)
0.42
" The disease group also had a lower area under the curve per dosing interval, steady-state concentration maximum, and dose-adjusted peak steady-state concentration."( Altered plasma pharmacokinetics of ceftiofur hydrochloride in cows affected with severe clinical mastitis.
Coetzee, JF; Gorden, PJ; Kleinhenz, MD; KuKanich, B; Lee, CJ; Wang, C; Wulf, LW, 2016
)
0.43
" MPC concentrations provide a dosing target which may serve to reduce amplification of bacterial subpopulations with reduced antimicrobial susceptibility."( Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau, JM; Fitch, SD, 2019
)
0.51
" Our aim was to determine Ceftiofur Sodium activity and optimize dosing regimens against the pathogen Haemophilus parasuis using an in vitro and ex vivo pharmacokinetics/pharmacodynamics modeling approach."( PK/PD modeling of Ceftiofur Sodium against Haemophilus parasuis infection in pigs.
Chen, X; Chen, XG; Chi, SQ; Hong, J; Li, XD; Liu, C; Sun, T; Wang, GS; Wu, LY; Yu, DJ, 2019
)
0.51
"There has been a lack of information about the inhibition of bovine medicines on bovine hepatic CYP450 at their commercial doses and dosing routes."( Assessment of Inhibition of Bovine Hepatic Cytochrome P450 by 43 Commercial Bovine Medicines Using a Combination of
Feenstra, KL; Hu, SX; Mazur, CA, 2019
)
0.51
"The aim of this work was to assess the inhibition of 43 bovine medicines on bovine hepatic CYP450 using a combination of in vitro assay and Cmax values from pharmacokinetic studies with their commercial doses and dosing routes in the literature."( Assessment of Inhibition of Bovine Hepatic Cytochrome P450 by 43 Commercial Bovine Medicines Using a Combination of
Feenstra, KL; Hu, SX; Mazur, CA, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.09510.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 8Mus musculus (house mouse)IC50 (µMol)35.70003.02003.02003.0200AID1209730
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier family 22 member 8Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
basolateral plasma membraneSolute carrier family 22 member 8Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID278240Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278238Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278262Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID541855Antimicrobial activity against Escherichia coli ATCC 29522 by microdilution assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID495749Antimicrobial activity against Salmonella enterica serotype Virchow 3464b by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID278246Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278253Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278234Antimicrobial activity against Salmonella enterica serovar Typhimurium GyrA S21-1 acrAB::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278261Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID278248Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278259Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278244Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID560899Antibacterial activity against cefoxitin-resistant Escherichia coli by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Characterization of cefoxitin-resistant Escherichia coli isolates from recreational beaches and private drinking water in Canada between 2004 and 2006.
AID278237Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278269Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID541856Antimicrobial activity against florfenicol-resistant Edwardsiella ictaluri M07-1 by microdilution assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID1209732Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method in presence of probenecid2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID278267Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 tolC::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278252Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278264Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278254Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID541857Antimicrobial activity against Escherichia coli ATCC 29522 carrying Edwardsiella ictaluri pM07-1 by microdilution assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID278232Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 GyrA S83F mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278242Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278231Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 tolC::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278257Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278265Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 gyrA+ with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID542773Antimicrobial activity against Escherichia coli J53 transformed with pHNPA1 carrying qnrB6 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID278271Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 tolC::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278266Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 acrAB::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278268Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID542759Antimicrobial activity against Escherichia coli Du19 expressing qnrB6 and CTX-M-9G genes by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID542770Antimicrobial activity against Escherichia coli J53 transformed with pHND2 carrying qnrB6 and CTX-M-9G genes by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID278233Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID495753Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime-cluvulanic acid by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID495750Antimicrobial activity against Escherichia coli J5 by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID1209730Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID542735Antimicrobial activity against Klebsiella pneumoniae D10 expressing aac(6')-Ib-cr, qnrB4, CTX-M-1G and DHA-1 genes by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID542771Antimicrobial activity against Escherichia coli J53 transformed with pHND3 carrying qnrB6 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID278247Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278229Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278243Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278241Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID522110Antimicrobial activity against Escherichia coli isolates producing extended-spectrum beta-lactamases bla(CTX-M-1), bla(CTX-M-32) and bla(SHV-12) isolated from Italian broiler flocks by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
High diversity of extended-spectrum beta-lactamases in Escherichia coli isolates from Italian broiler flocks.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID278260Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278258Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID495748Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID495751Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID278251Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278249Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278250Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278230Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 acrAB::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278239Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1209731Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID278270Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID542742Antimicrobial activity against Citrobacter freundii D26 expressing qnrB6 and CTX-M-9G genes by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID542772Antimicrobial activity against Escherichia coli J53 transformed with pHNDU1 carrying qnrB6 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID278228Antimicrobial activity against Salmonella enterica serovar Typhimurium S212007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID542737Antimicrobial activity against Klebsiella pneumoniae D24 expressing aac(6')-Ib-cr and CTX-M-9G genes by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID278236Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278263Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 tolC::Kan with GyrA D87G mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278256Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID542769Antimicrobial activity against Escherichia coli J53 transformed with pHND1 carrying DHA-1 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID278245Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278255Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 tolC::Kan with GyrA S83F, D87N, parC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID278235Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 tolC::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID495752Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID542768Antimicrobial activity against Escherichia coli J53 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID542766Antimicrobial activity against Escherichia coli PA11 expressing aac(6')-Ib-cr, qnrS1 and qepA genes by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (495)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.20)18.7374
1990's82 (16.57)18.2507
2000's127 (25.66)29.6817
2010's233 (47.07)24.3611
2020's52 (10.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.59 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index113.02 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (68.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials102 (20.08%)5.53%
Reviews0 (0.00%)6.00%
Reviews8 (1.57%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies31 (6.10%)4.05%
Observational0 (0.00%)0.25%
Observational1 (0.20%)0.25%
Other10 (100.00%)84.16%
Other366 (72.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]